GlaxoSmithKline (GS70) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

GlaxoSmithKline DE:GS70 is currently developing the following drugs: Gsk3862995b, Efimosfermin Alfa, Standard Of Care, Gsk5784283, Aletekitug, Gsk1070806, Gsk5784283, Adjuvanted Rsvpref3 Vaccine, Adjuvanted Rzv Vaccine, Bevacizumab, Mocertatug Rezetecan, Carboplatin, Bevacizumab, Gemcitabine, Paclitaxel, Pegylated Liposomal Doxorubicin, Mocertatug Rezetecan, Pembrolizumab, Dostarlimab, Gsk5733584, Camlipixant, Depemokimab, Gsk3511294, Midazolam, Gsk3772701, Pan-Salmonella-With-Alum Vaccine, Pan-Salmonella-Without-Alum Vaccine, Typhoid Vi Conjugate Vaccine, Typhibev, Gsk4425689a Sc, Gsk4425689a Iv, Hfa-152A, Hfa-134A, Control Vaccine, Rsv/Hmpv_V Low Dose Vaccine, Rsv/Hmpv_V Medium Dose Vaccine, Rsv/Hmpv_V High Dose Vaccine, Rsv/Hmpv_W Low Dose Vaccine, Rsv/Hmpv_W Medium Dose Vaccine, Rsv/Hmpv_W High Dose Vaccine, Rsv/Hmpv_X Low Dose Vaccine, Rsv/Hmpv_X Medium Dose Vaccine, Rsv/Hmpv_X High Dose Vaccine, Hmpv_Y Low Dose Vaccine, Hmpv_Y Medium Dose Vaccine, Hmpv_Y High Dose Vaccine, Hmpv_Z Low Dose Vaccine, Hmpv_Z Medium Dose Vaccine, Hmpv_Z High Dose Vaccine, Dexamethasone, Bortezomib, Belantamab Mafodotin, Gsk5926371, Dtpa, Boostrix, Dtpa Vaccine, G-Csf, Ris-Rez, Imatinib, Velzatinib, Gsk3772701 600 Mg, Gsk3772701 900 Mg, Gsk3772701 150 Mg, Gsk3772701 400 Mg, Gsk3772701 50 Mg, Licensed Seasonal Influenza Vaccine, Licensed Covid-19 Vaccine, Investigational Mrna Seasonal Flu/Covid-19 Combination Vaccine, Gsk5533524, Pcv20, Pn-Maps30plus, Mmrv, Mmrvns, Soc, Gepotidacin, Gsk5471713. These drug candidates are in various stages of clinical development as the company works toward FDA approval.